2 July 2026
Latham & Watkins Advises BridgeBio on Up to US$1 Billion Preferred Equity Investment, One of the Largest Preferred Investments for Public Biotechs Ever and the Largest in 2026
Advising firms
Deal team
20 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Drew Capurro Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Reza Mojtabaee-Zamani Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Eric Rice Lead | Latham & Watkins LLP | Partner | Not stated | Not stated |
| Jacob Walsh | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Brice Stewart | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Robertson Dorsett | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Bora Bozkurt | Latham & Watkins LLP | Partner | tax | Not stated |
| Farrah Yan | Latham & Watkins LLP | Associate | tax | Not stated |
| Josh Holian | Latham & Watkins LLP | Partner | antitrust | Not stated |
| Patrick English | Latham & Watkins LLP | Partner | antitrust | Not stated |
| Tomas Nilsson | Latham & Watkins LLP | Partner | antitrust | Not stated |
| Jana Dammann de Chapto | Latham & Watkins LLP | Partner | antitrust | Not stated |
| Jean Hyun | Latham & Watkins LLP | Associate | antitrust | Not stated |
| Amilia Kechagia | Latham & Watkins LLP | Associate | antitrust | Not stated |
| Nathan Beaton | Latham & Watkins LLP | Partner | FDA and healthcare | Not stated |
| Betty Pang | Latham & Watkins LLP | Partner | FDA and healthcare | Not stated |
| Taylore Williams | Latham & Watkins LLP | Associate | FDA and healthcare | Not stated |
| Robert Yeh | Latham & Watkins LLP | Counsel | IP/licensing | Not stated |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy and cybersecurity | Not stated |
17 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 1bn (US$1 billion)
- What the figure measures
- Issue size
- Client
- BridgeBio Pharma, Inc.Issuer
- Counterparties
- funds managed by Sixth Street (Investor)
funds managed by HealthCare Royalty, a business of KKR (Investor)